J
Junichi Yamaguchi
Researcher at Fujitsu
Publications - 86
Citations - 1285
Junichi Yamaguchi is an academic researcher from Fujitsu. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 55 publications receiving 930 citations. Previous affiliations of Junichi Yamaguchi include NTT Medical Center & Saitama Prefecture.
Papers
More filters
Journal ArticleDOI
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome.
Kazuo Kimura,Takeshi Kimura,Masaharu Ishihara,Yoshihisa Nakagawa,Koichi Nakao,Katsumi Miyauchi,Tomohiro Sakamoto,Kenichi Tsujita,Nobuhisa Hagiwara,Shunichi Miyazaki,Junya Ako,Hirokuni Arai,Hideki Ishii,Hideki Origuchi,Wataru Shimizu,Hirofumi Takemura,Yoshio Tahara,Yoshihiro Morino,Kenji Iino,Tomonori Itoh,Yoshitaka Iwanaga,Keiji Uchida,Hirohisa Endo,Ken Kongoji,Kenji Sakamoto,Hiroki Shiomi,Takao Shimohama,Atsushi Suzuki,Jun Takahashi,Ichiro Takeuchi,Akihito Tanaka,Toshihiro Tamura,Takahiro Nakashima,Teruo Noguchi,Daisuke Fukamachi,Tomohiro Mizuno,Junichi Yamaguchi,Kenji Yodogawa,Masami Kosuge,Shun Kohsaka,Hideaki Yoshino,Satoshi Yasuda,Hiroaki Shimokawa,Atsushi Hirayama,Takashi Akasaka,Kazuo Haze,Hisao Ogawa,Hiroyuki Tsutsui,Tsutomu Yamazaki +48 more
TL;DR: This document is an English version of JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome reported at the Japanese Circulation Society Joint Working Groups performed in 2018.
Journal ArticleDOI
Prognostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who underwent successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] Registry)
Junichi Yamaguchi,Hiroshi Kasanuki,Yasuhiro Ishii,Masahiro Yagi,Hiroshi Ogawa,Shin-ya Fujii,Hiroshi Koganei,Hisayuki Okada,Hirotaka Kimura,Toshinobu Horie,Kazuo Haze,Tetsuya Sumiyoshi,Takashi Honda +12 more
TL;DR: This study evaluated the impact of serum creatinine levels on in-hospital mortality in 1,359 consecutive patients with acute myocardial infarction (from a Japanese prospective multicenter registry) who underwent successful primary percutaneous coronary intervention (PCI).
Journal ArticleDOI
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Hiroshi Kasanuki,Nobuhisa Hagiwara,Saichi Hosoda,Tetsuya Sumiyoshi,Takashi Honda,Kazuo Haze,Michitaka Nagashima,Junichi Yamaguchi,Hideki Origasa,Mitsuyoshi Urashima,Hiroshi Ogawa +10 more
TL;DR: Although candesartan showed no significant differences in MACE compared with the non-ARB treatment group, the drug significantly reduced the incidence of new-onset diabetes and was better tolerated.
Journal ArticleDOI
Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.
Kentaro Jujo,Katsumi Saito,Issei Ishida,Yuho Furuki,Ahsung Kim,Yuki Suzuki,Haruki Sekiguchi,Junichi Yamaguchi,Hiroshi Ogawa,Nobuhisa Hagiwara +9 more
TL;DR: Tolvaptan, a vasopressin V2‐receptor antagonist, could reduce unfavourable furosemide‐induced effects during CHF treatment to reduce the need for loop diuretics.
Journal ArticleDOI
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Nobuhisa Hagiwara,Erisa Kawada-Watanabe,Ryo Koyanagi,Hiroyuki Arashi,Junichi Yamaguchi,Koichi Nakao,Tetsuya Tobaru,Hiroyuki Tanaka,Toshiaki Oka,Yasuhiro Endoh,Katsumi Saito,Tatsuro Uchida,Kunihiko Matsui,Hiroshi Ogawa +13 more
TL;DR: Although intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitvastatin monotherapy in ACS patients with dyslipidaemia, statin plus eZetIMibe may be more effective than statin monotherapyIn patients with higher cholesterol absorption; further confirmation is needed.